HPV-negative carcinoma of the uterine cervix: A distinct type of cervical cancer with poor prognosis

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 122, Issue 1, 2015, Pages 119-127

  Rodriguez Carunchio L ^a   Soveral, I ^a   Steenbergen, R D M ^b   Torne A ^a   Martinez, S ^a   Fuste P ^a   Pahisa, J ^a   Marimon, L ^a   Ordi, J ^a   Del Pino, M ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cervical cancer; human papillomavirus; p16; p53; prognosis; uterine cervix

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CLINICAL FEATURE; DISEASE FREE SURVIVAL; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; OVERALL SURVIVAL; PATIENT ASSESSMENT; POLYMERASE CHAIN REACTION; PREVALENCE; SERODIAGNOSIS; SPAIN; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; WART VIRUS; ADENOSQUAMOUS CARCINOMA; COHORT ANALYSIS; COLLOID CARCINOMA; GENETICS; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PROGNOSIS; UTERINE CERVIX TUMOR; VIROLOGY;

VIRUS DNA;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; DNA, VIRAL; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PROGNOSIS; UTERINE CERVICAL NEOPLASMS;

EID: 84920060845     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/1471-0528.13071     Document Type: Article

References (39)

1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.
2. Monsonego J,. Global challenges of cervical cancer prevention. Eur J Gynaecol Oncol 2000; 21: 533-9.
3. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11: 1048-56.
4. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM,. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2011; 128: 927-35.
5. Barreto CL, Martins DB, De Lima Filho JL, Magalhaes V,. Detection of Human Papillomavirus in biopsies of patients with cervical cancer, and its association with prognosis. Arch Gynecol Obstet 2013; 288: 643-8.
6. Higgins GD, Davy M, Roder D, Uzelin DM, Phillips GE, Burrell CJ,. Increased age and mortality associated with cervical carcinomas negative for human Papillomavirus RNA. Lancet 1991; 338: 910-13.
7. Riou G, Favre M, Jeannel D, Bourhis J, Le Doussal V, Orth G,. Association between poor prognosis in early-stage invasive cervical carcinomas and non-detection of HPV DNA. Lancet 1990; 335: 1171-4.
8. del Pino M, Rodriguez-Carunchio L, Alonso I, Torne A, Rodriguez A, Fuste P, et al. Clinical, colposcopic and pathological characteristics of cervical and vaginal high-grade lesions negative for HPV by Hybrid Capture 2. Gynecol Oncol 2011; 122: 515-20.
9. Clavel C, Cucherousset J, Lorenzato M, Caudroy S, Nou JM, Nazeyrollas P, et al. Negative human papillomavirus testing in normal smears selects a population at low risk for developing high-grade cervical lesions. Br J Cancer 2004; 90: 1803-8.
10. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119: 1095-101.
11. Saslow D, Runowicz CD, Solomon D, Moscicki AB, Smith RA, Eyre HJ, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002; 52: 342-62.
12. Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009; 124: 516-20.
13. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D,. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007; 197: 346-55.
14. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012; 62: 147-72.
15. Ordi J, Alonso I, Torne A, Esteve R, Sierra E, Campo E, et al. Human papillomavirus load in Hybrid Capture II assay: does increasing the cutoff improve the test? Gynecol Oncol 2005; 99: 313-19.
16. del Pino M, Garcia S, Fuste V, Alonso I, Fuste P, Torne A, et al. Value of p16(INK4a) as a marker of progression/regression in cervical intraepithelial neoplasia grade 1. Am J Obstet Gynecol 2009; 201: 488-7.
17. Bergeron C, Ordi J, Schmidt D, Trunk MJ, Keller T, Ridder R,. Conjunctive p16INK4a testing significantly increases accuracy in diagnosing high-grade cervical intraepithelial neoplasia. Am J Clin Pathol 2010; 133: 395-406.
18. Santos M, Landolfi S, Olivella A, Lloveras B, Klaustermeier J, Suarez H, et al. p16 overexpression identifies HPV-positive vulvar squamous cell carcinomas. Am J Surg Pathol 2006; 30: 1347-56.
19. de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ,. The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 1995; 4: 1057-62.
20. Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer CJ, Walboomers JM,. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 1997; 35: 791-5.
21. van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ,. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 2002; 40: 779-87.
22. Kleter B, van Doorn LJ, ter Schegget J, Schrauwen L, van Krimpen K, Burger M, et al. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol 1998; 153: 1731-9.
23. Kleter B, van Doorn LJ, Schrauwen L, Molijn A, Sastrowijoto S, ter Schegget J, et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 1999; 37: 2508-17.
24. Hesselink A, Berkhof J, van der Salm ML, van Splunter AP, Geelen TH, Van Kemenade FJ, et al. Clinical validation of the HPV-Risk assay: a novel, real-time PCR assay for the detection of high-risk human papillomavirus DNA by targeting the E7 region. J Clin Microbiol 2014; 52: 890-6.
25. Li Z, Austin RM, Guo M, Zhao C,. Screening test results associated with cancer diagnoses in 287 women with cervical squamous cell carcinoma. Arch Pathol Lab Med 2012; 136: 1533-40.
26. Szostek S, Klimek M, Zawilinska B, Rys J, Kope J, Daszkiewic E,. Detection of human papillomavirus in cervical cell specimens by hybrid capture and PCR with different primers. Acta Biochim Pol 2006; 53: 603-7.
27. Zaravinos A, Mammas IN, Sourvinos G, Spandidos DA,. Molecular detection methods of human papillomavirus (HPV). Int J Biol Markers 2009; 24: 215-22.
28. Jastania R, Geddie WR, Chapman W, Boerner S,. Characteristics of apparently false-negative digene hybrid capture 2 high-risk HPV DNA testing. Am J Clin Pathol 2006; 125: 223-8.
29. Guimera N, Lloveras B, Alemany L, Iljazovic E, Shin HR, Jung-Il S, et al. Laser capture microdissection shows HPV11 as both a causal and a coincidental infection in cervical cancer specimens with multiple HPV types. Histopathology 2013; 63: 287-92.
30. Guan P, Howell-Jones R, Li N, Bruni L, de Sanjose S, Franceschi S, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012; 131: 2349-59.
31. Igidbashian S, Schettino MT, Boveri S, Barberis M, Sandri MT, Carinelli S, et al. Tissue genotyping of 37 in situ and invasive cervical cancer with a concomitant negative HC2 HPV DNA test. J Low Genit Tract Dis 2014; 18: 87-91.
32. Lai CH, Huang HJ, Hsueh S, Chao A, Lin CT, Huang SL, et al. Human papillomavirus genotype in cervical cancer: a population-based study. Int J Cancer 2007; 120: 1999-2006.
33. Andersson S, Larson B, Hjerpe A, Silfversward C, Sallstrom J, Wilander E, et al. Adenocarcinoma of the uterine cervix: the presence of human papillomavirus and the method of detection. Acta Obstet Gynecol Scand 2003; 82: 960-5.
34. Clifford G, Franceschi S,. Members of the human papillomavirus type 18 family (alpha-7 species) share a common association with adenocarcinoma of the cervix. Int J Cancer 2008; 122: 1684-5.
35. Tornesello ML, Losito S, Benincasa G, Fulciniti F, Botti G, Greggi S, et al. Human papillomavirus (HPV) genotypes and HPV16 variants and risk of adenocarcinoma and squamous cell carcinoma of the cervix. Gynecol Oncol 2011; 121: 32-42.
36. Park KJ, Kiyokawa T, Soslow RA, Lamb CA, Oliva E, Zivanovic O, et al. Unusual endocervical adenocarcinomas: an immunohistochemical analysis with molecular detection of human papillomavirus. Am J Surg Pathol 2011; 35: 633-46.
37. Pirog EC, Lloveras B, Molijn A, Tous S, Guimera N, Alejo M, et al. HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases. Mod Pathol 2014; doi: 10.1038/modpathol.2014.55. [Epub ahead of print].
38. Alos L, Moyano S, Nadal A, Alobid I, Blanch JL, Ayala E, et al. Human papillomaviruses are identified in a subgroup of sinonasal squamous cell carcinomas with favorable outcome. Cancer 2009; 115: 2701-9.
39. Alonso I, Felix A, Torne A, Fuste V, del Pino M, Castillo P, et al. Human papillomavirus as a favorable prognostic biomarker in squamous cell carcinomas of the vagina. Gynecol Oncol 2012; 125: 194-9.